TZ9 | B2835

TZ9 is a triazine analogue inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B/HHR6B. It docks to the Rad6B catalytic site. It inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis of human breast cancer MDA-MB-231 cells. It inhibits proliferation of MDA-MB-231 cells with an IC₅₀ of 6 μM.

TZ9 is a triazine analogue inhibitor of human E2 ubiquitin-conjugating enzyme Rad6B/HHR6B. It docks to the Rad6B catalytic site. It inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and apoptosis of human breast cancer MDA-MB-231 cells. It inhibits proliferation of MDA-MB-231 cells with an IC₅₀ of 6 μM.

B2835 | TZ9 DataSheet

Alternate Name/Synonyms: TZ9; (4-amino-6-anilino-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate, (4-amino-6-(phenylamino)-1,3,5-triazin-2-yl)methyl 4-nitrobenzoate; Rad6 inhibitor; HHR6 inhibitor

Appearance: A crystalline solid

Formulation:

CAS Number: 1002789-86-7

Structure Available?: true

Peptide sequence:

Salt Form: false

Molecular Formula: C₁₇H₁₄N₆O₄

Molecular Weight: 366.33

Cell-Permeable?: True

Purity: ≥98%

Solubilities: ~30 mg/ml in DMSO and DMF in 0

Handling: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

Country of Origin: USA

Tag Line: An inhibitor of Rad6B/HHR6B

MDL Number:

PubChem CID: 7593228

SMILES: C1=CC=C(C=C1)NC2=NC(=NC(=N2)N)COC(=O)C3=CC=C(C=C3)[N+](=O)[O-]

InChi: InChI=1S/C17H14N6O4/c18-16-20-14(21-17(22-16)19-12-4-2-1-3-5-12)10-27-15(24)11-6-8-13(9-7-11)23(25)26/h1-9H,10H2,(H3,18,19,20,21,22)

InChi Key: RRRDZFQRNJTKHL-UHFFFAOYSA-N